tert-butyl (3S,4R)-3,4-diazidopyrrolidine-1-carboxylate | 945217-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl (3S,4R)-3,4-diazidopyrrolidine-1-carboxylate
• 英文别名: tert-Butyl cis-3,4-diazidopyrrolidine-1-carboxylate
• CAS: 945217-59-4
• 化学式: C₉H₁₅N₇O₂
• 分子量: 253.264
• InChiKey: YJMKJQUSMRAAFO-KNVOCYPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  58.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl (3S,4R)-3,4-diazidopyrrolidine-1-carboxylate 在 20% palladium hydroxide-activated charcoal 草酰氯 、 氢气 、 二甲基亚砜 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 tert-butyl 2-methyl-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxylate
  参考文献：
  名称：

  [EN] THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS
  [FR] DÉRIVÉS DE THIÉNO-PYRIDINE UTILISÉS COMME INHIBITEURS DE MEK

  摘要：

  一系列噻吩[2,3-6]吡啶衍生物，连接在取代苯胺基团的2-位置，其在3-位置被一个与吡咯啉-1-基环相连的羰基取代，后者又构成一个含杂原子的融合双环环系统的一部分，是人类MEK（MAPKK）酶的选择性抑制剂，在医学上具有益处，例如在治疗炎症、自身免疫、心血管、增殖（包括肿瘤学）和疼痛性疾病方面。

  公开号：

  WO2009153554A1
• 作为产物：
  描述：

  N-Boc-3-吡咯啉 在 四氧化锇 、 sodium azide 、 水 、 N-甲基吗啉氧化物 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 tert-butyl (3S,4R)-3,4-diazidopyrrolidine-1-carboxylate
  参考文献：
  名称：

  Discovery of 1-Pyrimidinyl-2-Aryl-4,6-Dihydropyrrolo [3,4-d]Imidazole-5(1H)-Carboxamide as a Novel JNK Inhibitor

  摘要：

  我们设计并合成了1-嘧啶基-2-芳基-4,6-二氢吡咯[3,4-d]咪唑-5(1H)-甲酰胺衍生物，作为选择性抑制剂针对c-Jun-N-末端激酶3 (JNK3)，这是治疗神经退行性疾病的靶点。基于先前研究中发现的化合物，设计了一种新颖的支架以改善药代动力学特性和活性，其中化合物18a，(R)-1-(2-((1-(环丙酰)吡咯烷-3-基)氨基)嘧啶-4-基)-2-(3,4-二氯苯基)-4,6-二氢吡咯[3,4-d]咪唑-5(1H)-甲酰胺，显示了最高的IC50值为2.69 nM。激酶分析结果还显示在38种激酶中对JNK3具有高度选择性，对JNK2、RIPK3和GSK3β具有轻微活性，这些激酶也已知参与神经细胞凋亡。

  DOI：

  10.3390/ijms21051698

文献信息

• Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
  申请人：Biftu Tesfaye

  公开号：US20090270467A1

  公开（公告）日：2009-10-29

  The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式（I）的新型取代氨基环己烷，其是二肽基肽酶-IV酶的抑制剂，并且对于涉及二肽基肽酶-IV酶的疾病的治疗或预防，例如糖尿病，特别是2型糖尿病，具有用途。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及二肽基肽酶-IV酶的疾病中的使用。
• Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07750034B2

  公开（公告）日：2010-07-06

  The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种结构式为（I）的新型取代氨基环己烷，其为二肽基肽酶-IV酶的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的用途。
• COMPOUND HAVING HIGHER INHIBITORY ACTIVITY ON PROTEIN KINASE G AND PREPARATION METHOD THEREOF
  申请人：Jenkem Technology Co.,Ltd. (Tianjin)

  公开号：US20170119736A1

  公开（公告）日：2017-05-04

  Disclosed are a compound of Formula I, having higher inhibition of protein kinase G (PKG) activity and pharmaceutically acceptable salts thereof. In Formula I, R 1 and R 2 are the same or different, each being independently chosen from the halogens, the C 1 -C 6 alkoxyl group, the C 1 -C 6 alkyl group, the C 2 -C 6 alkenyl group, and the C 2 -C 6 alkynyl group; R 3 is chosen from H, the halogens, the substituted or unsubstituted C 1 -C 6 alkyl group, C 3 -C 6 cycloalkyl group, C 2 -C 6 alkenyl group, and C 2 -C 6 alkynyl group, aryl group, and heteroaryl group; and n is an integer between 0 and 15. Also disclosed is a pharmaceutical composition comprising said compound, the use of the compound in treating pains, in particular chronic pain, a preparation method for the compound, and a new intermediate.
• US9925171B2
  申请人：——

  公开号：US9925171B2

  公开（公告）日：2018-03-27
• [EN] THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS<br/>[FR] DÉRIVÉS DE THIÉNO-PYRIDINE UTILISÉS COMME INHIBITEURS DE MEK
  申请人：UCB PHARMA SA

  公开号：WO2009153554A1

  公开（公告）日：2009-12-23

  A series of thieno[2,3-6]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.

  一系列噻吩[2,3-6]吡啶衍生物，连接在取代苯胺基团的2-位置，其在3-位置被一个与吡咯啉-1-基环相连的羰基取代，后者又构成一个含杂原子的融合双环环系统的一部分，是人类MEK（MAPKK）酶的选择性抑制剂，在医学上具有益处，例如在治疗炎症、自身免疫、心血管、增殖（包括肿瘤学）和疼痛性疾病方面。